[en] Type 1 diabetes (T1D) management is still complex. Some drugs have been proposed as adjunctive treatment to insulin for type 1 diabetes but results are not encouraging. Sodium-glucose cotransporter 2 (SGLT2) inhibitors act independently of insulin and initial proof-of-concept studies related to their use in T1D led to larger phase 3 trials. Several trials have demonstrated some beneficial and consistent effects as HbA1c, body weight and insulin dose reductions, and lesser glycaemic excursions. Nevertheless, adverse events were also reported, especially a higher rate of diabetic ketoacidosis when using gliflozins in T1D. Balance between positive and negative effects must be carefully studied in the near future with data from real-life and large trials dedicated to this potential new help in T1D.
Philips JC, Radermecker R. Le point sur les nouvelles insulines. Rev Med Suisse 2005;1:1936-41.
Radermecker R. La mesure continue du glucose dans la prise en charge du diabète: état des lieux et perspectives. Rev Med Suisse 2019;15:1444-7.
Scheen AJ. Rôle limité des médicaments hypoglycémiants oraux dans le diabète de type 1. Rev Med Liege 2013;68:16-21.
Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 2015;75:33-59.
Fattah, H., Vallon, V. The potential role of SGLT2 inhibitors in the treatment of type 1 diabetes mellitus. Drugs 2018;78:717-26.
Perkins BA,Cherney DZ, Partridge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 2014;37:1480-3.
Henry RR, Thakkar P, Tong C, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 2015;38:2258-65.
Sands AT, Zambrowicz BP, Rosenstock J, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care 2015;38:1181-8.
Garg SK, Henry RR, Banks P, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med 2017;377:2337-48.
Buse J, Garg S, Rosenstock J, et al. Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 Study. Diabetes Care 2018;41:1970-80.
Dandona P, Mathieu C, Philipp M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: The DEPICT-1 52-week study. Diabetes Care 2018;41:2552-9.
Mathieu C, Dandona P, Gillard P, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 Study): 24-week results from a randomized controlled trial. Diabetes Care 2018;41:1938-46.
Rosenstock J, Marquard J, Laffel LM, et al. Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: The EASE Trials. Diabetes Care 2018;41:2560-9.
Riddle MC, Cefalu W. SGLT-2 inhibitors for type 1 diabetes: an obvious choice or too good to be true? Diabetes Care 2018;41:2444-7.
Danne T, Cariou B, Buse JB, et al. Improved time in range and glycemic variability with sotagliflozin in combination with insulin in adults with type 1 diabetes: a pooled analysis of 24-week continuous glucose monitoring data from the inTandem program. Diabetes Care 2019;42:919-30.
Rodbard HW, Peters AL, Slee A, et al. The effect of canagliflozin, a sodium glucose cotransporter 2 inhibitor, on glycemic end points assessed by continuous glucose monitoring and patient-reported outcomes among people with type 1 diabetes. Diabetes Care 2017;40:171-80.
Mathieu C, Dandona P, Phillip M, et al. Glucose variables in type 1 diabetes studies with dapagliflozin: pooled analysis of continuous glucose monitoring data from DEPICT-1 and -2. Diabetes Care 2019;42:1081-7.
Bae JP, Lage MJ, Mo D, et al. Obesity and glycemic control in patients with diabetes mellitus: Analysis of physician electronic health records in the US from 2009-2011. J Diabetes Complications 2016;30:212-20.
Isaacs D, Yager S, Parker M, et al. Adjunct antihyperglycemic agents in overweight and obese adults with type 1 diabetes. Ann Pharmacother 2018;53:371-84.
Lunder M, Janic M, Japelj A, et al. Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus. Cardiovasc Diabetol 2018;17:153-61.
Scheen AJ. An update on the safety of SGLT2 inhibitors. Expert Opin Drug Saf 2019;18:295-311.
Danne T, Garg S, Peters AL, et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care 2019;42:1147-54.
